Global "blue screen" crisis does not affect long-term prospects, Baird gives CrowdStrike (CRWD.US) an "outperform" rating.
CrowdStrike provided several financial updates at its annual cybersecurity conference, and although there have been some visibility challenges recently, the company believes that these updates are mostly positive.
Investment bank Baird said that despite some visibility challenges for CrowdStrike (CRWD.US) recently, the company's latest financial updates are mostly positive. The bank gave it an "outperform" rating with a target price of $315.
CrowdStrike provided several financial updates at its annual cybersecurity conference, and although there have been some visibility challenges recently, the bank believes that these updates are mostly positive.
Analyst Shrenik Kothari stated, "CrowdStrike remains committed to achieving a $10 billion ARR goal this fall. However, following the global 'blue screen' crisis on July 19, short-term visibility challenges have brought some uncertainties, leading us to lower our near-term expectations."
Kothari pointed out that contract extensions and delayed spending "have suppressed some momentum in annual recurring revenue (ARR)," resulting in a $60 million impact for the second half of this year.
Nevertheless, Kothari remains optimistic about CrowdStrike's long-term prospects, projecting cloud security ARR to be between $2.5 billion and $3 billion by fiscal year 2031. Additionally, identity protection is expected to reach $1 billion to $1.5 billion, and next-generation security information and event management is projected to reach $1.5 billion to $2 billion.
The company also stated that by 2029, its broader addressable market opportunity will reach $250 billion, exceeding next year's $116 billion.
Kothari stated, "CrowdStrike maintains a total retention rate of 98%, highlighting user loyalty and platform stickiness, with the lowest churn rate. Through the Falcon Flex model and customer commitment packages, the company will continue to deepen relationships with existing customers, focusing on expanding and accelerating module adoption."
Related Articles

"Citigroup gives Biohaven (BHVN.US) a 'buy' rating, bullish on the potential of its core drug rimegepant receiving FDA approval."

HK Stock Market Move | ASMPT(00522) rose by more than 5%, and its wholly-owned subsidiary will become a key shareholder of Shenzhen Original Advanced Compounds, effectively promoting international cooperation in the semiconductor industry.

It is a good opportunity to enter! JP Morgan: Adobe (ADBE.US) valuation is low, AI and price increases together build a growth moat.
"Citigroup gives Biohaven (BHVN.US) a 'buy' rating, bullish on the potential of its core drug rimegepant receiving FDA approval."

HK Stock Market Move | ASMPT(00522) rose by more than 5%, and its wholly-owned subsidiary will become a key shareholder of Shenzhen Original Advanced Compounds, effectively promoting international cooperation in the semiconductor industry.

It is a good opportunity to enter! JP Morgan: Adobe (ADBE.US) valuation is low, AI and price increases together build a growth moat.
